SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

Aldeyra Therapeutics Announces Receipt Of Minutes From Dry Eye Disease Pre-NDA Meeting With FDA tones

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration

Benzinga · 09/14/2022 08:05

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company remains on schedule to submit an NDA in the fourth quarter of 2022 requesting marketing approval of the novel RASP modulator reproxalap, an investigational new drug, for the treatment of dry eye disease.